University of Pittsburgh Clinical and Translational Science Institute

匹兹堡大学临床与转化科学研究所

• 批准号: 10267454
• 负责人: STEVEN E REIS
• 金额: $ 97.65万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-11-01 至 2021-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10267454
• 关键词: 2019-nCoV; Academic Medical Centers; Adult; Alabama; Antibodies; Antibody titer measurement; Back; Biological Assay; Biological Markers; Blood specimen; COVID-19; COVID-19 detection; COVID-19 diagnosis; COVID-19 outbreak; COVID-19 pandemic; Clinical; Clinical Sciences; Communicable Diseases; Community Health; Consent; County; Data; Development; Diagnostic Reagent Kits; Disease; Economics; Enrollment; Enzyme-Linked Immunosorbent Assay; Epidemic; Ethnic group; Extramural Activities; Funding; Future; General Population; Geography; Health; Herd Immunity; Home; Humoral Immunities; Immune; Immune response; Immunity; Immunoglobulin G; Immunoglobulin M; Individual; Infection; Infectious Diseases Research; Institutes; Knowledge; Life Cycle Stages; Longevity; Measures; Monitor; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; Natural History; Outcome; Participant; Phase; Population; Prevalence; Race; Recontacts; SARS-CoV-2 antibody; SARS-CoV-2 immunity; SARS-CoV-2 spike protein; Sampling; Seroprevalences; Serum; Special Population; Surveys; Testing; Translational Research; Underrepresented Populations; United States; Universities; Viral; Virus; antibody detection; antibody test; clinical center; cohort; emerging pathogen; follow-up; health economics; insight; mortality; novel; novel virus; pandemic disease; pathogen; programs; response; screening; social; vaccination strategy

ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating effect on the physical, social, and economic health of communities throughout the world. To evaluate the sero-prevalence of immunity against SARS-COV-2 in the United States, this scientific partnership of Clinical and Translational Science Awardees (CTSAs) at academic medical centers (University of Alabama and University of Pittsburgh) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease identified, enrolled, and obtained blood samples from 11,300 adults who have not been diagnosed with COVID-19 representing almost every county in the US and all major racial and ethnic groups. We will now seek consent from these participants to provide follow-up data and blood samples and 6 and 12 months after enrollment (Aim 1) and determine the immune attributes associated with health outcomes (Aim 2), including for those in underrepresented populations and across the life course. This collaborative partnership of the intramural NIAID program and extramurally funded CTSA Hubs will efficiently survey, obtain blood samples from, and determine changes in the prevalence of SARS-CoV-2 antibodies in a large, heterogeneous cohort of adults without known clinical COVID-19 disease. Knowledge gained from this seroprevalence study will advance our understanding of SARS-CoV-2 humoral immunity at the population level and inform population strategies for vaccination – both for the COVID-19 pandemic and future epidemics involving novel pathogens.

摘要 由新型SARS-COV-2病毒引发的大流行继续对非洲产生破坏性影响， 世界各地社区的物质、社会和经济健康。评估血清流行率， 针对SARS-COV-2的免疫力在美国，这个临床和转化的科学伙伴关系， 学术医疗中心的科学奖获得者（CTSA）（亚拉巴马大学和匹兹堡大学） 国家过敏和传染病研究所（NIAID）传染病实验室 从11，300名未被诊断出患有糖尿病的成年人中确定，招募并获得血液样本。 COVID-19几乎代表了美国的每个县以及所有主要种族和民族。我们现在将 征求这些参与者的同意，以提供随访数据和血液样本，并在6个月和12个月后 入组（目标1）并确定与健康结果相关的免疫属性（目标2），包括 为那些在代表性不足的人群和整个生命过程。这种合作伙伴关系的 校内NIAID计划和校外资助的CTSA中心将有效地调查，获得血液样本 从，并确定在一个大的，异质性队列的SARS-CoV-2抗体的患病率的变化， 没有已知临床COVID-19疾病的成年人。从这项血清阳性率研究中获得的知识将 提高我们对SARS-CoV-2体液免疫在人群水平的认识，并告知人群 疫苗接种策略--包括针对COVID-19大流行和未来涉及新型病原体的流行。